Cleo Diagnostics Ltd (ASX:COV)

Market Cap	56.54M
Revenue (ttm)	210.81K
Net Income (ttm)	-3.10M
Shares Out	128.50M
EPS (ttm)	-0.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	25,849
Average Volume	153,465
Open	0.4450
Previous Close	0.4750
Day's Range	0.4300 - 0.4600
52-Week Range	0.1600 - 0.6200
Beta	n/a
RSI	54.03
Earnings Date	May 28, 2025

About Cleo Diagnostics

Cleo Diagnostics Ltd, a medical diagnostics and devices company, focuses on the development and commercializing of non-invasive blood tests to detect ovarian cancer in Australia. The company provides CleoDX pre-surgical triage tests which measures a combination of biomarkers in serum to provide an accurate determination of malignancy risk prior to surgical referral. It also focuses on developing and testing intellectual property and patents. The company was incorporated in 2021 and is based in Melbourne, Australia.

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2021
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: COV